相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Cardiovascular Disease, Cancer, and Mortality Among People With Type 2 Diabetes and Alcoholic or Nonalcoholic Fatty Liver Disease Hospital Admission
Sarah H. Wild et al.
DIABETES CARE (2018)
Prevalence of nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus A meta-analysis
Wenjie Dai et al.
MEDICINE (2017)
Effects of Dapagliflozin on Body Composition and Liver Tests in Patients with Nonalcoholic Steatohepatitis Associated with Type 2 Diabetes Mellitus: A Prospective, Open-label, Uncontrolled Study
Hiroshi Tobita et al.
CURRENT THERAPEUTIC RESEARCH-CLINICAL AND EXPERIMENTAL (2017)
Comparison of Ipragliflozin and Pioglitazone Effects on Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes: A Randomized, 24-Week, Open-Label, Active-Controlled Trial
Daisuke Ito et al.
DIABETES CARE (2017)
Management of Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes: A Call to Action
Fernando Bril et al.
DIABETES CARE (2017)
Empagliflozin reduces body weight and indices of adipose distribution in patients with type 2 diabetes mellitus
Ian J. Neeland et al.
DIABETES & VASCULAR DISEASE RESEARCH (2016)
Pharmacodynamic Effects of Single and Multiple Doses of Empagliflozin in Patients With Type 2 Diabetes
Tim Heise et al.
CLINICAL THERAPEUTICS (2016)
3. Comprehensive Medical Evaluation and Assessment of Comorbidities
DIABETES CARE (2016)
Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study
Matthew James Armstrong et al.
LANCET (2016)
The SGLT2 inhibitor empagliflozin improves insulin sensitivity in db/db mice both as monotherapy and in combination with linagliptin
Matthias Kern et al.
METABOLISM-CLINICAL AND EXPERIMENTAL (2016)
Empagliflozin (an SGLT2 inhibitor), alone or in combination with linagliptin (a DPP-4 inhibitor), prevents steatohepatitis in a novel mouse model of non-alcoholic steatohepatitis and diabetes
Teruo Jojima et al.
DIABETOLOGY & METABOLIC SYNDROME (2016)
Probing SGLT2 as a therapeutic target for diabetes: Basic physiology and consequences
Linda A. Gallo et al.
DIABETES & VASCULAR DISEASE RESEARCH (2015)
Impact of empagliflozin added on to basal insulin in type 2 diabetes inadequately controlled on basal insulin: a 78-week randomized, double-blind, placebo-controlled trial
J. Rosenstock et al.
DIABETES OBESITY & METABOLISM (2015)
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Bernard Zinman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Empagliflozin as Add-On to Metformin in Patients With Type 2 Diabetes: A 24-Week, Randomized, Double-Blind, Placebo-Controlled Trial
Hans-Ulrich Haering et al.
DIABETES CARE (2014)
Improved Glucose Control With Weight Loss, Lower Insulin Doses, and No Increased Hypoglycemia With Empagliflozin Added to Titrated Multiple Daily Injections of Insulin in Obese Inadequately Controlled Type 2 Diabetes
Julio Rosenstock et al.
DIABETES CARE (2014)
Empagliflozin improves glycaemic and weight control as add-on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: a 24-week, randomized, placebo-controlled trial
C. S. Kovacs et al.
DIABETES OBESITY & METABOLISM (2014)
The role of hepatic lipids in hepatic insulin resistance and type 2 diabetes
Rachel J. Perry et al.
NATURE (2014)
Non-alcoholic fatty liver disease
Naveed Sattar et al.
BMJ-BRITISH MEDICAL JOURNAL (2014)
Comparison of empagliflozin and glimepiride as add-on to metformin in patients with type 2 diabetes: a 104-week randomised, active-controlled, double-blind, phase 3 trial
Martin Ridderstrale et al.
LANCET DIABETES & ENDOCRINOLOGY (2014)
Empagliflozin as Add-on to Metformin Plus Sulfonylurea in Patients With Type 2 Diabetes A 24-week, randomized, double-blind, placebo-controlled trial
Hans-Ulrich Haering et al.
DIABETES CARE (2013)
Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 3 trial
Michael Roden et al.
LANCET DIABETES & ENDOCRINOLOGY (2013)
Prevalence of and Risk Factors for Hepatic Steatosis and Nonalcoholic Fatty Liver Disease in People With Type 2 Diabetes: the Edinburgh Type 2 Diabetes Study
Rachel M. Williamson et al.
DIABETES CARE (2011)
Prevalence and associated factors of non-alcoholic fatty liver disease in patients with type-2 diabetes mellitus
Nathalie C. Leite et al.
LIVER INTERNATIONAL (2009)
Pathogenesis of type 2 diabetes: tracing the reverse route from cure to cause
R. Taylor
DIABETOLOGIA (2008)
Prevalence of elevated liver enzymes in Type 2 diabetes mellitus and its association with the metabolic syndrome
G. Forlani et al.
JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION (2008)
Liver eat is increased in type 2 diabetic patients and underestimated by serum alanine aminotransferase compared with equally obese nondiabetic sub jets
Anna Kotronen et al.
DIABETES CARE (2008)
Elevated serum alanine transaminase in patients with type 1 or type 2 diabetes mellitus
J. West et al.
QJM-AN INTERNATIONAL JOURNAL OF MEDICINE (2006)
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis
Renata Belfort et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Elevations in markers of liver injury and risk of type 2 diabetes - The insulin resistance atherosclerosis study
AJG Hanley et al.
DIABETES (2004)
分享论文
